A Phase 2 Study of MEDI-575 in Adult Subjects with Recurrent Glioblastoma Multiforme
18 Years - 95 Years
Endpoint Classification: Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2017 by MedImmune, LLC
No locations available
|Experimental: MEDI-575, 25 mg/kg|
MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
MEDI-575 as an IV infusion.